Review



ciap2  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc ciap2
    Ciap2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 182 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ciap2/c-IAP2+Rabbit+mAb/bio_rxiv__64898__2026__03__09__710628-232-33-34
    Average 95 stars, based on 182 article reviews
    ciap2 - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    Immunohistochemistry:

    Article Title: E3 ligase Skp2-mediated stabilization of survivin contributes to radioresistance.
    Article Snippet: The inhibitors, including MG132, cycloheximide (CHX), Necrostatin-1 (Nec1), z-VAD-FMK and Chloroquine (CQ) from Selleck Chemicals (Houston, TX). .. Antibodies against Survivin (#2808; IB: 1:1000; IHC: 1: 2000), Skp2 (#2652, IB:1:2000, IHC: 1:1000), γ-H2AX (#9718; IB: 1:1000; IF: 1: 800), p-CDK1 Thr161 (#9114; 1:1000), p-Akt Ser473 (#4060; IB: 1:1000; IHC: 1: 50), α-Tubulin (#2125; 1:5000), VDAC1 (#4866; 1: 3000), Bax (#14796; 1:1000), Akt (#4691; 1:2000), anti-mouse IgG HRP (#7076; 1:10000), Flag-tag (#8146; 1:1000), cleaved-caspase 3 (#9664; IB: 1:1000; IHC: 1: 2000), p-Wee1 Ser642 (#4910; 1:1000), p-Survivin T34 (#8888; 1:1000), cytochrome C (#11940; 1:1000), cIAP2 (#3130; 1:1000), cIAP1 (#7065; 1:1000), Ub-k48 (#8081; 1:1000), β-actin (#3700; 1:1000) were obtained from Cell Signaling Technology, Inc. (Beverly, MA). .. Antibodies against Ki67 (#ab15580; IHC: 1:2000) and FBXL7 (#ab59149; 1:1000) were purchased from Abcam (Cambridge, UK).

    Western Blot:

    Article Title: Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma
    Article Snippet: Cells were counted using a Countess (ThermoFisher Scientific, UK) and the mean count ± the standard error of the mean (SEM) from 3 independent experiments was calculated. .. Western blot analysis was carried out as previously described using antibodies targeting phospho-(S473)-Akt (Cell Signaling Technology Cat# 4060, RRID:AB_2315049), phospho-(T308)-Akt (Cell Signaling Technology Cat# 4056, RRID:AB_331163), pan- Akt (Cell Signaling Technology Cat# 2920, RRID:AB_1147620), PTEN (Cell Signaling Technology Cat# 9559, RRID:AB_390810), PARP (Cell Signaling Technology Cat# 9532, RRID:AB_659884), phospho-γ-H2AX (Cell Signaling Technology Cat# 9718, RRID:AB_2118009), cIAP1 (Cell Signaling Technology Cat# 7065, RRID:AB_10890862), cIAP2 (Cell Signaling Technology Cat# 3130, RRID:AB_10693298), XIAP (Cell Signaling Technology Cat# 2045, RRID:AB_2214866) and Survivin (Cell Signaling Technology Cat# 2808, RRID:AB_2063948). .. Mouse monoclonal antibodies were used in conjunction with anti-mouse IgG, HRP-linked Antibody (Cell Signaling Technology Cat# 7076, RRID:AB_330924).

    Article Title: Epstein-barr virus latent membrane protein 1 targets cIAP1, cIAP2 and TRAF2 for proteasomal degradation to activate the non-canonical NF-κB pathway
    Article Snippet: .. For immunoblot analysis, Cell Signaling Technology antibodies against cIAP1 (D5G9), cIAP2 (58C7), XIAP (3B6), TRAF1 (45D3), TRAF3 (#4729), TRAF5 (#D3E2R), FLAG (M2, #2368), V5 (#D3H8Q), NIK (#4994) and ubiquitin (P4D1, #3936) were used at 1:1000 for immunoblot analysis. .. Antibodies against TRAF2 (Proteintech 26846–1-AP), TRAF2 (Invitrogen SD205–06), HA (Abcam ab9110), and p100/52 (EMD Millipore #05–361) were used at 1:1000.

    Article Title: Epstein-barr virus latent membrane protein 1 targets cIAP1, cIAP2 and TRAF2 for proteasomal degradation to activate the non-canonical NF-κB pathway.
    Article Snippet: .. For immunoblot analysis, Cell Signaling Technology antibodies against cIAP1 (D5G9), cIAP2 (58C7), XIAP (3B6), TRAF1 (45D3), TRAF3 (#4729), TRAF5 (#D3E2R), FLAG (M2, #2368), V5 (#D3H8Q), NIK (#4994) and ubiquitin (P4D1, #3936) were used at 1:1000 for immunoblot analysis. .. Antibodies against TRAF2 (Proteintech 26846–1-AP), TRAF2 (Invitrogen SD205–06), HA (Abcam ab9110), and p100/52 (EMD Millipore #05–361) were used at 1:1000.

    Ubiquitin Proteomics:

    Article Title: Epstein-barr virus latent membrane protein 1 targets cIAP1, cIAP2 and TRAF2 for proteasomal degradation to activate the non-canonical NF-κB pathway
    Article Snippet: .. For immunoblot analysis, Cell Signaling Technology antibodies against cIAP1 (D5G9), cIAP2 (58C7), XIAP (3B6), TRAF1 (45D3), TRAF3 (#4729), TRAF5 (#D3E2R), FLAG (M2, #2368), V5 (#D3H8Q), NIK (#4994) and ubiquitin (P4D1, #3936) were used at 1:1000 for immunoblot analysis. .. Antibodies against TRAF2 (Proteintech 26846–1-AP), TRAF2 (Invitrogen SD205–06), HA (Abcam ab9110), and p100/52 (EMD Millipore #05–361) were used at 1:1000.

    Article Title: Epstein-barr virus latent membrane protein 1 targets cIAP1, cIAP2 and TRAF2 for proteasomal degradation to activate the non-canonical NF-κB pathway.
    Article Snippet: .. For immunoblot analysis, Cell Signaling Technology antibodies against cIAP1 (D5G9), cIAP2 (58C7), XIAP (3B6), TRAF1 (45D3), TRAF3 (#4729), TRAF5 (#D3E2R), FLAG (M2, #2368), V5 (#D3H8Q), NIK (#4994) and ubiquitin (P4D1, #3936) were used at 1:1000 for immunoblot analysis. .. Antibodies against TRAF2 (Proteintech 26846–1-AP), TRAF2 (Invitrogen SD205–06), HA (Abcam ab9110), and p100/52 (EMD Millipore #05–361) were used at 1:1000.

    Article Title: CARD14 signalosome formation is associated with its endosomal relocation and mTORC1-induced keratinocyte proliferation
    Article Snippet: .. The following antibodies were used: anti-FLAG (M2) (Sigma, #F1804, or #F3165); anti-tubulin (TAT-1); p-IKK1/2 (2078S); p-p105 (CST, #4806); RelA (CST, #8242); p-ERK1/2 (CST, #9101); p-p38 (CST, #4511); HOIP (Merck, #SAB2102031); HOIL-1/RBCK1 (Atlas Antibodies, #HPA024185); SHARPIN (Proteintech, #14626); TRAF2 (Abcam, #ab126758); TRAF6 (Abcam, #ab40675); BCL10 (SCBT, #sc-5273); MALT1 (SCBT, #sc-28246; CST, #2494); ABIN1 (Ubiquigent, #68-0002-100); A20 (CST, #5630S); DIABLO (CST, #D5S3R); cIAP1 (CST, #7065); cIAP2 (CST, #3130); TAK1 (CST, #4505S); IKK2 (CST, #2684); EpsinR (Thermo Fisher Scientific, #PA5-60308); AP2B1 (SCBT, #sc-58226); AP2A1 (Abcam, #ab128950); total ubiquitin (CST, #3933); M1-linked ubiquitin (Merck, LUB9, #MABS451); K48-linked ubiquitin (CST, #8081); p-TAK1 (CST, #4536); p-TAB2 (CST, #8155); p-TRAF2 (CST, #13908); p-A20 (CST, #63523); p-MKK4 (CST, #9156); p-MK2 (CST, #3007); p-MEK1/2 (CST, #9121); p-JNK (CST, #9255/9251); p-JUN (CST, #9261/9164); p-FRA1 (CST, #5841); p-ATF2 (CST, #9225); p-mTOR (CST, #2481/2488); p-p70 S6K (CST, #9234); p-eIF4B (CST, #3591); p-S6 Ribosomal (CST, #2215). ..



    Similar Products

    c iap2  (ABclonal Biotechnology)
    94
    ABclonal Biotechnology c iap2
    Enhancement of doxorubicin-induced SaOS-2 cell apoptosis by SQLE inhibition ( A ) Representative flow cytometry scatter plots of SaOS-2 cells following Annexin V-FITC/PI dual staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their combinations for 48 h. ( B ) Quantitative analysis showing the corresponding percentages of total apoptotic cells derived from ( A ). ( C ) Representative flow cytometry histograms of mitochondrial membrane potential (MMP) disruption in SaOS-2 cells using MitoView™ 633 staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. ( D ) Quantitative analysis showing the proportion of MMP-disrupted cells normalized to the control group, derived from ( C ). ( E , F ) Western blot analysis of key anti-apoptotic proteins in (BCL-2, BCL-XL, <t>c-IAP2,</t> and c-FLIP) SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( E ) and their corresponding relative band intensities calculated relative to the control group ( F ). ( G , H ) Western blot analysis of pro-apoptotic proteins (cleaved PARP-1 and cleaved caspase-3) in SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( G ) and quantitative analysis of protein expression levels relative to the control group ( H ). ( I ) Cell viability analysis via MTT assay in SaOS-2 cells treated with 150 nM doxorubicin, 75 μM terbinafine, or their combination for 48 h, evaluated in the absence or presence of apoptosis inhibitor 50 μM Z-VAD-FMK. Data are expressed as the mean ± SD ( n = 3 independent experiments). #, ##, and ### indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 compared to the control group, respectively. *, **, and *** indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 for specific comparisons between experimental groups.
    C Iap2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ciap2/cIAP2+Rabbit+pAb/pmc13603089-29-4-45
    Average 94 stars, based on 1 article reviews
    c iap2 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti birc3  (ABclonal Biotechnology)
    94
    ABclonal Biotechnology anti birc3
    Enhancement of doxorubicin-induced SaOS-2 cell apoptosis by SQLE inhibition ( A ) Representative flow cytometry scatter plots of SaOS-2 cells following Annexin V-FITC/PI dual staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their combinations for 48 h. ( B ) Quantitative analysis showing the corresponding percentages of total apoptotic cells derived from ( A ). ( C ) Representative flow cytometry histograms of mitochondrial membrane potential (MMP) disruption in SaOS-2 cells using MitoView™ 633 staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. ( D ) Quantitative analysis showing the proportion of MMP-disrupted cells normalized to the control group, derived from ( C ). ( E , F ) Western blot analysis of key anti-apoptotic proteins in (BCL-2, BCL-XL, <t>c-IAP2,</t> and c-FLIP) SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( E ) and their corresponding relative band intensities calculated relative to the control group ( F ). ( G , H ) Western blot analysis of pro-apoptotic proteins (cleaved PARP-1 and cleaved caspase-3) in SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( G ) and quantitative analysis of protein expression levels relative to the control group ( H ). ( I ) Cell viability analysis via MTT assay in SaOS-2 cells treated with 150 nM doxorubicin, 75 μM terbinafine, or their combination for 48 h, evaluated in the absence or presence of apoptosis inhibitor 50 μM Z-VAD-FMK. Data are expressed as the mean ± SD ( n = 3 independent experiments). #, ##, and ### indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 compared to the control group, respectively. *, **, and *** indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 for specific comparisons between experimental groups.
    Anti Birc3, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ciap2/cIAP2+Rabbit+pAb/pm42413735-173-18-20
    Average 94 stars, based on 1 article reviews
    anti birc3 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    gfp tagged orf plasmids  (OriGene)
    94
    OriGene gfp tagged orf plasmids
    Enhancement of doxorubicin-induced SaOS-2 cell apoptosis by SQLE inhibition ( A ) Representative flow cytometry scatter plots of SaOS-2 cells following Annexin V-FITC/PI dual staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their combinations for 48 h. ( B ) Quantitative analysis showing the corresponding percentages of total apoptotic cells derived from ( A ). ( C ) Representative flow cytometry histograms of mitochondrial membrane potential (MMP) disruption in SaOS-2 cells using MitoView™ 633 staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. ( D ) Quantitative analysis showing the proportion of MMP-disrupted cells normalized to the control group, derived from ( C ). ( E , F ) Western blot analysis of key anti-apoptotic proteins in (BCL-2, BCL-XL, <t>c-IAP2,</t> and c-FLIP) SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( E ) and their corresponding relative band intensities calculated relative to the control group ( F ). ( G , H ) Western blot analysis of pro-apoptotic proteins (cleaved PARP-1 and cleaved caspase-3) in SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( G ) and quantitative analysis of protein expression levels relative to the control group ( H ). ( I ) Cell viability analysis via MTT assay in SaOS-2 cells treated with 150 nM doxorubicin, 75 μM terbinafine, or their combination for 48 h, evaluated in the absence or presence of apoptosis inhibitor 50 μM Z-VAD-FMK. Data are expressed as the mean ± SD ( n = 3 independent experiments). #, ##, and ### indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 compared to the control group, respectively. *, **, and *** indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 for specific comparisons between experimental groups.
    Gfp Tagged Orf Plasmids, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ciap2/cIAP2+(BIRC3)+(NM_182962)+Human+Tagged+ORF+Clone/pmc13183958-281-6-9
    Average 94 stars, based on 1 article reviews
    gfp tagged orf plasmids - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ciap2  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc ciap2
    Enhancement of doxorubicin-induced SaOS-2 cell apoptosis by SQLE inhibition ( A ) Representative flow cytometry scatter plots of SaOS-2 cells following Annexin V-FITC/PI dual staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their combinations for 48 h. ( B ) Quantitative analysis showing the corresponding percentages of total apoptotic cells derived from ( A ). ( C ) Representative flow cytometry histograms of mitochondrial membrane potential (MMP) disruption in SaOS-2 cells using MitoView™ 633 staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. ( D ) Quantitative analysis showing the proportion of MMP-disrupted cells normalized to the control group, derived from ( C ). ( E , F ) Western blot analysis of key anti-apoptotic proteins in (BCL-2, BCL-XL, <t>c-IAP2,</t> and c-FLIP) SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( E ) and their corresponding relative band intensities calculated relative to the control group ( F ). ( G , H ) Western blot analysis of pro-apoptotic proteins (cleaved PARP-1 and cleaved caspase-3) in SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( G ) and quantitative analysis of protein expression levels relative to the control group ( H ). ( I ) Cell viability analysis via MTT assay in SaOS-2 cells treated with 150 nM doxorubicin, 75 μM terbinafine, or their combination for 48 h, evaluated in the absence or presence of apoptosis inhibitor 50 μM Z-VAD-FMK. Data are expressed as the mean ± SD ( n = 3 independent experiments). #, ##, and ### indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 compared to the control group, respectively. *, **, and *** indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 for specific comparisons between experimental groups.
    Ciap2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ciap2/c-IAP2+Rabbit+mAb/bio_rxiv__64898__2026__03__09__710628-232-33-34
    Average 95 stars, based on 1 article reviews
    ciap2 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    anti ciap2  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc anti ciap2
    Enhancement of doxorubicin-induced SaOS-2 cell apoptosis by SQLE inhibition ( A ) Representative flow cytometry scatter plots of SaOS-2 cells following Annexin V-FITC/PI dual staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their combinations for 48 h. ( B ) Quantitative analysis showing the corresponding percentages of total apoptotic cells derived from ( A ). ( C ) Representative flow cytometry histograms of mitochondrial membrane potential (MMP) disruption in SaOS-2 cells using MitoView™ 633 staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. ( D ) Quantitative analysis showing the proportion of MMP-disrupted cells normalized to the control group, derived from ( C ). ( E , F ) Western blot analysis of key anti-apoptotic proteins in (BCL-2, BCL-XL, <t>c-IAP2,</t> and c-FLIP) SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( E ) and their corresponding relative band intensities calculated relative to the control group ( F ). ( G , H ) Western blot analysis of pro-apoptotic proteins (cleaved PARP-1 and cleaved caspase-3) in SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( G ) and quantitative analysis of protein expression levels relative to the control group ( H ). ( I ) Cell viability analysis via MTT assay in SaOS-2 cells treated with 150 nM doxorubicin, 75 μM terbinafine, or their combination for 48 h, evaluated in the absence or presence of apoptosis inhibitor 50 μM Z-VAD-FMK. Data are expressed as the mean ± SD ( n = 3 independent experiments). #, ##, and ### indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 compared to the control group, respectively. *, **, and *** indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 for specific comparisons between experimental groups.
    Anti Ciap2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ciap2/c-IAP2+Rabbit+mAb/pm41609943-98-82-84
    Average 95 stars, based on 1 article reviews
    anti ciap2 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    anti ciap2  (ABclonal Biotechnology)
    94
    ABclonal Biotechnology anti ciap2
    Enhancement of doxorubicin-induced SaOS-2 cell apoptosis by SQLE inhibition ( A ) Representative flow cytometry scatter plots of SaOS-2 cells following Annexin V-FITC/PI dual staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their combinations for 48 h. ( B ) Quantitative analysis showing the corresponding percentages of total apoptotic cells derived from ( A ). ( C ) Representative flow cytometry histograms of mitochondrial membrane potential (MMP) disruption in SaOS-2 cells using MitoView™ 633 staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. ( D ) Quantitative analysis showing the proportion of MMP-disrupted cells normalized to the control group, derived from ( C ). ( E , F ) Western blot analysis of key anti-apoptotic proteins in (BCL-2, BCL-XL, <t>c-IAP2,</t> and c-FLIP) SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( E ) and their corresponding relative band intensities calculated relative to the control group ( F ). ( G , H ) Western blot analysis of pro-apoptotic proteins (cleaved PARP-1 and cleaved caspase-3) in SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( G ) and quantitative analysis of protein expression levels relative to the control group ( H ). ( I ) Cell viability analysis via MTT assay in SaOS-2 cells treated with 150 nM doxorubicin, 75 μM terbinafine, or their combination for 48 h, evaluated in the absence or presence of apoptosis inhibitor 50 μM Z-VAD-FMK. Data are expressed as the mean ± SD ( n = 3 independent experiments). #, ##, and ### indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 compared to the control group, respectively. *, **, and *** indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 for specific comparisons between experimental groups.
    Anti Ciap2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ciap2/cIAP2+Rabbit+pAb/10__1016_slash_j__molstruc__2026__145294-354-22-24
    Average 94 stars, based on 1 article reviews
    anti ciap2 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ciap2  (Human Protein Atlas)
    86
    Human Protein Atlas ciap2
    Enhancement of doxorubicin-induced SaOS-2 cell apoptosis by SQLE inhibition ( A ) Representative flow cytometry scatter plots of SaOS-2 cells following Annexin V-FITC/PI dual staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their combinations for 48 h. ( B ) Quantitative analysis showing the corresponding percentages of total apoptotic cells derived from ( A ). ( C ) Representative flow cytometry histograms of mitochondrial membrane potential (MMP) disruption in SaOS-2 cells using MitoView™ 633 staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. ( D ) Quantitative analysis showing the proportion of MMP-disrupted cells normalized to the control group, derived from ( C ). ( E , F ) Western blot analysis of key anti-apoptotic proteins in (BCL-2, BCL-XL, <t>c-IAP2,</t> and c-FLIP) SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( E ) and their corresponding relative band intensities calculated relative to the control group ( F ). ( G , H ) Western blot analysis of pro-apoptotic proteins (cleaved PARP-1 and cleaved caspase-3) in SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( G ) and quantitative analysis of protein expression levels relative to the control group ( H ). ( I ) Cell viability analysis via MTT assay in SaOS-2 cells treated with 150 nM doxorubicin, 75 μM terbinafine, or their combination for 48 h, evaluated in the absence or presence of apoptosis inhibitor 50 μM Z-VAD-FMK. Data are expressed as the mean ± SD ( n = 3 independent experiments). #, ##, and ### indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 compared to the control group, respectively. *, **, and *** indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 for specific comparisons between experimental groups.
    Ciap2, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ciap2/ciap2/pm41457346-391-6-3
    Average 86 stars, based on 1 article reviews
    ciap2 - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Enhancement of doxorubicin-induced SaOS-2 cell apoptosis by SQLE inhibition ( A ) Representative flow cytometry scatter plots of SaOS-2 cells following Annexin V-FITC/PI dual staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their combinations for 48 h. ( B ) Quantitative analysis showing the corresponding percentages of total apoptotic cells derived from ( A ). ( C ) Representative flow cytometry histograms of mitochondrial membrane potential (MMP) disruption in SaOS-2 cells using MitoView™ 633 staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. ( D ) Quantitative analysis showing the proportion of MMP-disrupted cells normalized to the control group, derived from ( C ). ( E , F ) Western blot analysis of key anti-apoptotic proteins in (BCL-2, BCL-XL, c-IAP2, and c-FLIP) SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( E ) and their corresponding relative band intensities calculated relative to the control group ( F ). ( G , H ) Western blot analysis of pro-apoptotic proteins (cleaved PARP-1 and cleaved caspase-3) in SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( G ) and quantitative analysis of protein expression levels relative to the control group ( H ). ( I ) Cell viability analysis via MTT assay in SaOS-2 cells treated with 150 nM doxorubicin, 75 μM terbinafine, or their combination for 48 h, evaluated in the absence or presence of apoptosis inhibitor 50 μM Z-VAD-FMK. Data are expressed as the mean ± SD ( n = 3 independent experiments). #, ##, and ### indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 compared to the control group, respectively. *, **, and *** indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 for specific comparisons between experimental groups.

    Journal: Antioxidants

    Article Title: Targeting SQLE-Mediated Cholesterol Metabolism to Promote Oxidative Stress and Attenuate Drug Resistance in Osteosarcoma

    doi: 10.3390/antiox15091122

    Figure Lengend Snippet: Enhancement of doxorubicin-induced SaOS-2 cell apoptosis by SQLE inhibition ( A ) Representative flow cytometry scatter plots of SaOS-2 cells following Annexin V-FITC/PI dual staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their combinations for 48 h. ( B ) Quantitative analysis showing the corresponding percentages of total apoptotic cells derived from ( A ). ( C ) Representative flow cytometry histograms of mitochondrial membrane potential (MMP) disruption in SaOS-2 cells using MitoView™ 633 staining. Cells were treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. ( D ) Quantitative analysis showing the proportion of MMP-disrupted cells normalized to the control group, derived from ( C ). ( E , F ) Western blot analysis of key anti-apoptotic proteins in (BCL-2, BCL-XL, c-IAP2, and c-FLIP) SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( E ) and their corresponding relative band intensities calculated relative to the control group ( F ). ( G , H ) Western blot analysis of pro-apoptotic proteins (cleaved PARP-1 and cleaved caspase-3) in SaOS-2 cells treated with doxorubicin (150 nM), terbinafine (50 and 75 μM), or their respective combinations for 48 h. β-actin was used as the internal control. Representative immunoblots ( G ) and quantitative analysis of protein expression levels relative to the control group ( H ). ( I ) Cell viability analysis via MTT assay in SaOS-2 cells treated with 150 nM doxorubicin, 75 μM terbinafine, or their combination for 48 h, evaluated in the absence or presence of apoptosis inhibitor 50 μM Z-VAD-FMK. Data are expressed as the mean ± SD ( n = 3 independent experiments). #, ##, and ### indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 compared to the control group, respectively. *, **, and *** indicate p ≤ 0.05, p ≤ 0.005, and p ≤ 0.001 for specific comparisons between experimental groups.

    Article Snippet: Antibodies specific to c-FLIP, c-IAP2, BCL-2, BCL-XL, p-GSK3, GSK3, p-ERK, ERK, N-cadherin, vimentin, cleaved caspase-3, cyclin-B, and β-actin were obtained from Cell Signaling Technology (Danvers, MA, USA), whereas antibodies specific to MT1MMP, p-mTOR, mTOR, p-AKT, AKT, PARP-1, GPX-4, FSP-1, CDC25C, and p21 were purchased from Abclonal (Woburn, MA, USA).

    Techniques: Inhibition, Flow Cytometry, Staining, Analysis, Derivative Assay, Membrane, Disruption, Control, Western Blot, Expressing, MTT Assay